Peter Attia MD302 - Confronting a metabolic epidemic: how to prevent, diagnose, & manage liver disease
CHAPTERS
- 0:00 – 8:14
Julia Wattacheril's Background and the Missing Liver Support Device
After a cold-open clip on early-stage disease, Peter Attia introduces Julia Wattacheril, a transplant hepatologist, and asks about her training. They discuss why the liver has no extracorporeal support, covering the MARS machine, accessory livers, and a story about baboons used as a bridge.
- •Julia is a transplant hepatologist who splits her time between transplant and general liver care, with a focus on MASLD and metabolism
- •Lungs, heart and kidneys have extracorporeal support, but the liver has no real equivalent
- •Devices like the MARS machine exist; 3D-printed or accessory livers are being pursued
- •Most liver disease is chronic, so the acute phase is where a bridge is needed
- •Alcohol studies in baboons taught researchers a lot about liver injury
- 8:14 – 13:17
What the Liver Does: Its Essential Functions
Julia describes the liver's size and location and its more than 300 functions, grouping them into metabolism, immune function, clotting-protein synthesis, and detoxification. Peter offers his own big four: metabolism including glucose regulation, synthetic function, detoxification, and lipoprotein handling.
- •The liver weighs about three and a half pounds, sits under the right rib cage, and is the largest internal organ
- •Parenchymal diseases affect the whole liver, while cholestatic diseases affect the bile ducts
- •Liver dysfunction shows up as bleeding disorders because of lost clotting-protein synthesis
- •Peter highlights the liver's glucose regulation and its role in lipoprotein clearance and generation
- 13:17 – 26:03
History of Liver Disease, Transplantation, and Hepatitis B vs. C
The conversation covers how liver disease was historically blamed on toxins, alcohol and viruses, and how transplantation began with Starzl. They discuss current transplant indications, acetaminophen injury, and the differences between hepatitis C and B, including cancer risk and the meaning of fibrosis stages.
- •Alcohol and viral hepatitis are the top chronic adult indications for transplant, with alcohol surging during the pandemic
- •Under 10% of transplants at Julia's center are for acute liver failure, and acetaminophen is a subfraction of those
- •Hepatitis C became treatable with direct-acting antivirals, and hepatitis B has an effective vaccine
- •Hepatitis B can lead to liver cancer independent of fibrosis progression, so screening occurs regardless of scarring
- •Cirrhosis is stage four scarring, not a death sentence, and signals increased monitoring
- 26:03 – 35:39
How the Liver Handles Excess Calories and Insulin Resistance
Peter asks how the liver handles nutrients normally and in pathology. Julia explains hepatocyte stress, fat storage beyond 5%, de novo lipogenesis versus dietary input, and the bidirectional relationship between liver fat and insulin resistance. Peter adds the liver's role in producing glucose for the brain.
- •Steatosis is defined as 5% or more of hepatocytes containing fat
- •The liver was not designed to store fat; overwhelmed subcutaneous compartments deliver more substrate to it
- •Liver fat can be detected before insulin resistance develops, and the exact timing and mechanism remain undetermined
- •HOMA-IR and glucose tolerance tests help catch early insulin resistance
- •The liver supplies glucose to the brain between meals
- 35:39 – 43:45
Diagnosing Steatosis and Spotting Atypical Cases
They discuss how steatosis is diagnosed, noting that standard ultrasound misses fat below about 30% and that MRI-PDFF and FibroScan's CAP score are more sensitive. Julia explains that outliers, such as a lean person with a very high CAP score, should prompt consideration of rarer causes, and the extreme phenotypes of lean and South Asian patients.
- •Plain ultrasound generally doesn't detect steatosis under 30%, so a negative ultrasound doesn't rule it out
- •MRI-PDFF is costly; point-of-care CAP on FibroScan uses attenuated ultrasound
- •Absent expected metabolic features, a high fat score suggests genetic or rarer causes
- •Peter shares an example of undiagnosed hemochromatosis found incidentally on MRI
- •Lean patients and some ancestries can develop aggressive disease
- 43:45 – 49:29
How Ethanol Injures the Liver
Peter asks why ethanol is toxic to the liver, and Julia walks through alcohol dehydrogenase, acetaldehyde and the redox overload that drives inflammation. They touch on overlap with metabolic injury histology and sex differences in alcohol metabolism.
- •Alcohol is converted to acetaldehyde, which then becomes carbon dioxide and water
- •Overwhelming this pathway shifts redox potential and attracts free radicals and immune cells
- •Alcohol and metabolic injury can look histologically similar
- •Sex differences were once attributed to body composition, but gene expression and hormones are also variables
- •About fourteen grams of alcohol define a standard drink
- 49:29 – 1:04:00
Alcohol Beyond the Liver and Counseling Patients on Drinking
Julia explains that alcohol's harms extend to the brain, heart, pancreas and cancer risk, and describes how she counsels patients on intake. She details how to define a standard drink, ask about drinking patterns, and use the PEth test.
- •Alcohol affects other organs and carries oncologic risk, including breast cancer, as noted by Julia
- •Aminotransferases are poor markers of drinking; fat on elastography is an earlier signal
- •Standard drinks are 1.5 oz liquor, 5 oz wine, 12 oz beer
- •Moderate intake per the CDC is two drinks daily for men and one for women
- •PEth reflects roughly one to two weeks of drinking and is available through Quest and LabCorp
- 1:04:00 – 1:20:38
AST and ALT: What Normal Means and Why Peter's Pattern Might Occur
Julia explains what AST and ALT are and why they rise when hepatocytes burst. They discuss reference ranges versus optimal values, and Julia works through Peter's own labs, asking about exercise, alcohol, CK and medications such as ezetimibe.
- •AST and ALT are necroinflammatory markers, not true liver function tests, and also exist in muscle
- •Julia considers under 30 good, and persistent levels of one and a half to two times the upper limit of normal prompt a workup
- •Peter notes lab cutoffs reflect population distributions that have drifted
- •Recent exercise, muscle injury and alcohol can affect the results
- •A fibrosis calculator like FIB-4 can check for accumulated injury
- 1:20:38 – 1:27:51
Serum Biomarker Panels, GGT, and Pediatric vs. Adult Patterns
Peter asks about the LabCorp NASH score, and Julia explains that proprietary serum tests leave a lot of intermediate-risk results, so liver specialists rely more on imaging. She then covers how fatty liver is distributed differently in children (portal) versus adults (around the central vein) and how GGT and alkaline phosphatase fit in.
- •Serum scores give steatosis and fibrosis estimates, but a negative result isn't full reassurance
- •Imaging-based tests are more sensitive and easier to counsel patients with
- •Pediatric fatty liver is portal-based and may raise GGT and alkaline phosphatase
- •Adult disease centers on the central vein, with ballooned hepatocytes as a precursor to cell death
- 1:27:51 – 1:39:49
Imaging and Tools for a Full Liver Health Assessment
Julia lays out how she evaluates early-stage patients, starting with history, basic labs and FIB-4, then moving to elastography. She distinguishes FibroScan from ultrasound and MR elastography, explains the fat score versus scar score, and covers recreational drugs and statins in relation to elevated LFTs.
- •Referrals for early disease usually come from abnormal aminotransferases or abnormal imaging, and alcohol should always be asked about
- •FibroScan gives a fat score and a scar score and works in most but not all patients
- •Elastography works by vibrating the liver, with a normal liver soft like a sponge and a cirrhotic one hard like a brick
- •Past injection or intranasal drug use, old transfusions, and dental work abroad are hepatitis risk factors, not current cannabis use
- •Julia sees real statin-related liver injury very rarely, while Peter says his practice tends to be aggressive about elevations
- 1:39:49 – 1:46:32
From NAFLD to MASLD: The Nomenclature Change
Julia explains why the field moved from NAFLD and NASH to MASLD and MASH: the old name defined the disease by what it wasn't and carried stigma. The new umbrella of steatotic liver disease includes MASLD, MetALD, alcohol-related, monogenic and cryptogenic categories.
- •NAFLD was defined by exclusion and the terms 'alcoholic' and 'fatty' felt stigmatizing to patients
- •Steatotic liver disease is the umbrella, with MASLD as one subgroup
- •Other categories include MetALD, alcohol-related, monogenic, and cryptogenic
- •Medications that cause liver fat should also be reviewed
- •MASLD is the most prevalent liver disease globally
- 1:46:32 – 1:56:50
MASLD Diagnosis, Prevalence, and When to Look for Zebras
They discuss diagnostic criteria for MASLD, including that metabolic syndrome is not required, and Peter argues for an organ-centric view of metabolic health. Julia estimates 25 to 35 percent prevalence, and they cover when to refer for rare conditions.
- •Diagnosis combines imaging or biopsy evidence of steatosis with cardiometabolic risk, and any one cardiometabolic feature can qualify
- •Peter argues the liver should be the first organ to look at for metabolic health
- •Prevalence is estimated at 25 to 35 percent, and screening isn't yet recommended for steatotic liver disease
- •Lean outliers with high ALT and early stiffness should be referred to specialists for rare causes
- 1:56:50 – 2:10:20
Lifestyle Management: Exercise, Nutrition, Coffee, and Fructose
Julia describes how she approaches lifestyle intervention, including exercise assessment, resistance work, dietitian referral and glucose handling. She highlights coffee's association with benefit, and she and Peter discuss the difficulty of isolating fructose's effect from weight loss and insulin resistance.
- •Most MASLD patients face more cardiovascular risk than liver risk
- •Julia emphasizes resistance and aerobic activity and building habits, especially for patients with low muscle mass
- •Up to three cups of black coffee are associated with anti-fibrotic and metabolic benefits, but the active component is unknown
- •Studies of fructose are hard to disentangle from weight loss and insulin resistance
- •Julia favors practical advice like avoiding processed foods over singling out one component
- 2:10:20 – 2:18:23
GLP-1 Agonists, Liver Staging, and Biopsy's Role
Peter asks whether GLP-1 drugs are the most effective treatment for MASLD, and Julia explains when she brings them in and why she discusses weight regain. They then cover how biopsy fits in today and what stages 1 through 4 of fibrosis mean, including that early cirrhosis may be reversible.
- •Julia reaches for GLP-1 agonists in diabetes, obesity or overweight with moderate fibrosis, with a long-term view on weight regain and muscle loss
- •Their liver effects are hard to separate from overall weight loss
- •Biopsy is used to exclude autoimmune disease, for trials, before surgery, and as a tiebreaker
- •NASH is fat plus inflammation and ballooning; scarring is staged one to four
- •Progression between stages averages five to seven years, and even early cirrhosis may be reversible
- 2:18:23 – 2:26:18
Early-Stage Risk: Cardiovascular, Diabetes, and Liver Cancer
Peter asks Julia to confirm that early-stage patients are closer to heart disease and cancer than liver failure. She describes empowering patients with fat and scar scores, quantifies HCC risk at 3 to 5% per year in cirrhosis, and notes that earlier screening in MASLD is an open question.
- •Early disease patients are more at risk from cardiovascular outcomes and diabetes than liver failure
- •Julia frames a high fat score with normal scar score as modifiable within months
- •HCC risk is about 3 to 5% per year with cirrhosis, with screening every six months
- •Whether to screen earlier in MASLD is an area of active interest
- •Cirrhosis can be diagnosed in people in their 30s and 40s and isn't comparable to stage four cancer
- 2:26:18 – 2:37:07
Emerging Drugs, Supplements, and Peter's Takeaways
Julia discusses resmetirom and other pipeline agents like FXR agonists, FGFs and PPAR agonists, and the difficulty of trial endpoints. They address vitamin E and choline, mitochondrial uncouplers, and then Peter summarizes the main takeaways and Julia clarifies that MACE is not a primary trial endpoint.
- •Resmetirom, a thyroid hormone receptor agonist, showed promise in a phase III trial, though the population was heavily of European ancestry
- •Other agents target FGF, FXR and PPAR pathways, and histologic benefit doesn't always meet FDA endpoints
- •Vitamin E has potential downsides, including prostate cancer and mortality signals at certain doses
- •Combination therapy is likely the route for mitochondrial-targeting approaches
- •Peter's takeaways: be thorough in diagnosis, alcohol and metabolic overlap is significant, and the condition is treatable and reversible
